Immupharma PLC Incanthera announces Rule 23 Notice re NEX listing (1304D)
February 17 2020 - 3:00AM
UK Regulatory
TIDMIMM
RNS Number : 1304D
Immupharma PLC
17 February 2020
ImmuPharma PLC
("ImmuPharma" or the "Company")
Oncology specialist Incanthera, in which ImmuPharma currently
has a 14.0% shareholding, announces Rule 23 Notice in advance to
quoting on NEX Exchange Growth Market
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM), a
specialist drug discovery and development company, notes that the
NEX Exchange Growth Market ("NEX") has today released a
pre-admission announcement under Rule 23 of the intention of
Incanthera plc ("Incanthera"), a specialist oncology company, to
quote on NEX.
ImmuPharma currently holds a 14.0% shareholding in Incanthera
following its subscription for shares in September 2018. Following
admission, ImmuPharma will retain 7,272,740 shares in Incanthera,
representing 11.9%.
At the time of the subscription, ImmuPharma was also granted
warrants to subscribe for additional ordinary shares in Incanthera
at any time over five years from the initial subscription. These
warrants have been carried over into the new listed plc company and
now total 7,272,740 warrants. The exercise price has been rebased
to the issue price.
Commenting on the announcement, Dimitri Dimitrou, CEO of
ImmuPharma said:
"We are delighted to note Incanthera's imminent quote on
NEX.
"Incanthera's diverse oncology pipeline has blockbuster
potential. We are confident of the medium to long term prospects of
the business, but we are particularly excited at the potential near
term commercialisation of the lead product Sol, for skin cancer and
other topical indications.
"As a major shareholder, with a tangible stake in the future
success of Incanthera, we look forward to the creation of further
value for our shareholders as Incanthera moves forward".
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014. ("MAR").
For further information please contact:
ImmuPharma PLC ( www.immupharma.com )
Tim McCarthy, Chairman + 44 (0) 207 152 4080
Dimitri Dimitriou, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin, Henry Todd +44 (0) 203 36 8 8974
Stanford Capital Partners (Joint Broker)
Patrick Claridge, John Howes +44 (0) 203 815 8880
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
4Reliance (Euronext Growth Listing Sponsor) +32 (0) 2 747 02 60
Jean-Charles Snoy
Degroof Petercam (Liquidity Provider) +32 (0) 2 287 95 34
Erik De Clippel
Backstage Communication
Olivier Duquaine +32 (0) 477 504 784
Jean-Louis Dubrule +32 (0) 497 50 84 03
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio includes novel
peptide therapeutics for autoimmune diseases, metabolic diseases
and cancer. The lead program, LupuzorTM, is a first-in class
autophagy immunomodulator which is in Phase III for the treatment
of lupus and preclinical analysis suggest therapeutic activity for
many other autoimmune diseases that share the same autophagy
mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on
29 November 2019, an exclusive licence and development agreement
and trademark agreement for Lupuzor(TM) to fund a new international
Phase III trial for Lupuzor(TM) and commercialise in the US. For
additional information about ImmuPharma please visit
www.immupharma.com . ImmuPharma's LEI (Legal Entity Identifier)
code: 213800VZKGHXC7VUS895.
About Incanthera Limited
Incanthera Limited was formed in 2010 as a spin-out from the
Institute of Cancer Therapeutics at Bradford University and is
targeting the treatment of cancer through a portfolio of unique
technologies. Having successfully commercialised its lead product
in 2017, it is actively acquiring and developing technologies to
further enhance its portfolio of cancer therapeutics. For more
information, please visit www.incanthera.com
About NEX
NEX Exchange (formerly known as ISDX) is the ICAP Securities and
Derivatives Exchange. The NEX Exchange Growth Market is an equity
market for small and medium-sized ambitious, growth enterprises.
Typically its admission requirements are less stringent than those
for quoting on AIM.
In accordance with Rule 23 of the Growth Market Rules, a NEX
Exchange Corporate Adviser must submit the information no less than
10 business days prior to the intended admission date, and NEX
Exchange will release the pre-admission announcement by RIS under
the heading "NEX Exchange" on the date of submission of the
form.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCFIFFTFVIELII
(END) Dow Jones Newswires
February 17, 2020 03:00 ET (08:00 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024